PNC-27

PNC-27 is a peptide designed to target and destroy cancer cells by inducing necrosis. It works
by binding to a protein called HDM-2, which is often found on the surface of cancer cells, and
creating pores in the cell membrane, leading to cell death. While preclinical studies have shown

promising results, PNC-27 is not approved by the FDA for use in the United States and has
been the subject of FDA warnings due to safety concerns and unapproved marketing as a
cancer treatment.
Here’s a more detailed explanation:
Targeting HDM-2:
PNC-27 is designed to specifically target HDM-2, a protein that is often overexpressed in cancer
cells.
Membrane-Active Peptide:
It’s a membrane-active peptide, meaning it interacts with and disrupts the cell membrane.
Pore Formation:
PNC-27’s interaction with HDM-2 on cancer cell membranes leads to the formation of pores,
causing the cells to lyse (burst).